MedAlliance Launches Two PTCA Balloons to Complement SELUTION SLR™ Drug-Eluting Balloon

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

How To Control a Radio Frequency (RF) Process

The radio frequency welding and manufacturing process uses electromagnetic energy and pressure to fuse and permanently bond vinyl, thermoplastic, and coated materials to produce a specific product - all according to customer requirements. Using this RF sealing process, a distinct, one-piece perpetual bond is formulated that is both solid and resistant to ripping or tearing. But how is this process controlled, and with what specific tools? Read on.

MedAlliance has launched ORIGIN SC and ORIGIN NC, two high performance balloons for vessel preparation. These very much complement SELUTION SLR™, its novel sirolimus-eluting balloon per the company.

ORIGIN SC is a semi-compliant (SC) PTCA balloon with a very low crossing profile, making it an excellent choice for challenging lesions. ORIGIN SC offers one of the broadest portfolio of sizes available for an SC balloon, including 1.00 mm, 1.25 mm, 1.50 mm and 1.75 mm balloon diameters to treat very small vessels and complex cases.

ORIGIN NC is a non-compliant (NC) PTCA balloon, combining high pressure tolerance and controlled compliance with an optimal crossing profile for the most challenging cases. Origin NC’s minimal balloon longitudinal growth ensures focused dilatation force on the target lesion, minimizing the risk of damaging healthy tissue. ORIGIN NC also offers one of the lowest crossing profiles among all categories of PTCA balloon catheter currently available. It is particularly appropriate when facing tight stenoses in calcified, fibrotic lesions.

Drug-Eluting Balloons (DEBs) such as SELUTION SLR are designed to effectively deliver drug to the lesion site rather than dilate the vessel. This is why PTCA balloons designed for vessel preparation such as ORIGIN SC and ORIGIN NC are particularly appropriate in a pre-dilation role. These balloons, however, do not have to be used exclusively in conjunction with SELUTION SLR: they can be used on their own, for example to pre-dilate a vessel prior to stent implantation or to post-dilate a coronary stent to achieve accurate and controlled stent expansion.

“We are excited to be broadening our balloon portfolio with the ORIGIN range which complements our flagship DEB SELUTION SLR”, said Jeffrey B. Jump, Chairman and CEO of MedAlliance. “This is just the start of our product expansion program to vertically integrate high quality products for the benefit of patients around the world”.

MedAlliance’s DEB technology involves unique MicroReservoirs made from biodegradable polymer intermixed with the anti-restenotic drug sirolimus. These MicroReservoirs provide controlled and sustained release of the drug for up to 90 days1. Extended release of sirolimus from stents has been proven highly efficacious in both coronary and peripheral vasculatures. MedAlliance’s proprietary CAT™ (Cell Adherent Technology) enables the MicroReservoirs to be coated onto balloons and adhere to the vessel lumen when delivered via an angioplasty balloon.

SELUTION SLR was awarded CE Mark Approval for the treatment of peripheral artery disease in February 2020 and for the treatment of coronary arterial disease in May 2020.  It is now available in Europe and all other countries where the CE Mark is recognized.

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.